Purpose: The development of highly effective targeted agents for chronic lymphocytic leukemia offers the potential for fixed-duration combinations that achieve deep remissions without cytotoxic chemotherapy.

Patients and Methods: This phase II study tested a combination regimen of obinutuzumab, ibrutinib, and venetoclax for a total of 14 cycles in both patients with treatment-naive (n = 25) and relapsed or refractory (n = 25) chronic lymphocytic leukemia to determine the response to therapy and safety.

Results: The primary end point was the rate of complete remission with undetectable minimal residual disease by flow cytometry in both the blood and bone marrow 2 months after completion of treatment, which was 28% in both groups. The overall response rate at that time was 84% in treatment-naive patients and 88% in relapsed or refractory patients. At that time, 67% of treatment-naive patients and 50% of relapsed or refractory patients had undetectable minimal residual disease in both the blood and marrow. At a median follow-up of 24.2 months in treatment-naive patients and 21.5 months in relapsed or refractory patients, the median progression-free and overall survival times were not yet reached, with only 1 patient experiencing progression and 1 death. Neutropenia and thrombocytopenia were the most frequent adverse events, followed by hypertension. Grade 3 or 4 neutropenia was experienced by 66% of patients, with more events in the relapsed or refractory cohort. There was only 1 episode of neutropenic fever. A favorable impact on both perceived and objective cognitive performance during treatment was observed.

Conclusion: The combination regimen of obinutuzumab, ibrutinib, and venetoclax offers time-limited treatment that results in deep remissions and is now being studied in phase III cooperative group trials.

INTRODUCTION
Targeted agents have transformed the way chronic lymphocytic leukemia (CLL) is treated. These agents have superior treatment outcomes with decreased toxicity compared with chemoimmunotherapy and are particularly important for cytogenetically high-risk patients. They also hold the potential for combination regimens that result in high rates of deep remission, allowing for time-limited treatment without cytotoxic chemotherapy. To investigate this, we designed and tested a novel fixed-duration triplet combination of obinutuzumab, ibrutinib, and venetoclax and studied it in both patients with treatment-naive (TN) and relapsed or refractory (RR) CLL. Ibrutinib is an inhibitor of Bruton’s tyrosine kinase (BTK) in the B-cell receptor signaling cascade, and venetoclax inhibits B-cell lymphoma protein 2 (Bcl-2) interaction with select BH3 domain proteins, thereby promoting apoptosis. Both agents have superior progression-free survival (PFS) when compared with chemoimmunotherapy. They have complementary mechanisms of action in preclinical testing with overlapping toxicities limited to cytopenias, making them suitable for combination. An anti-CD20 monoclonal antibody was also included because these agents have consistently improved outcomes when combined with chemotherapy. Obinutuzumab was chosen because it has superior efficacy and higher rates of achieving undetectable minimal residual disease (MRD) compared with rituximab.

Treatment was given for a total of 14 cycles (28 days each) and then stopped. The 3 agents were introduced...
CONTEXT

Key Objective
To determine the safety and preliminary efficacy of combination obinutuzumab, ibrutinib, and venetoclax given for a fixed duration in both patients with treatment-naive and relapsed or refractory chronic lymphocytic leukemia (CLL).

Knowledge Generated
This combination was overall tolerable for the majority of patients but resulted in substantial hematologic toxicity. Remissions with no detectable residual CLL in both the blood and the bone marrow occurred in at least half of the patients, demonstrating that deep remissions can be achieved with this combination, which is given for a little longer than 1 year.

Relevance
This triplet regimen had sufficient activity to warrant testing in randomized phase III studies to determine whether it should be a new standard treatment of CLL.

PATIENTS AND METHODS

The study was conducted at The Ohio State University (ClinicalTrials.gov identifier: NCT02427451), approved by the Cancer Institutional Review Board, and conducted in accordance with the Declaration of Helsinki. The data cutoff date was November 1, 2018.

Eligibility
Eligible patients were ≥ 18 years old with a diagnosis of CLL or small lymphocytic lymphoma. TN patients had to meet criteria for treatment as defined by the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) guidelines. RR patients had to require treatment in the opinion of a study investigator.

Patients had to have an Eastern Oncology Cooperative Group performance status of ≤ 1. Serum creatinine had to be ≤ 2 mg/dL or creatinine clearance had to be ≥ 50 mL/ min/1.73 m². Patients with a known BTK cysteine 481 mutation or who had CLL that was refractory to or progressed during ibrutinib were excluded. Full eligibility criteria are provided in the Data Supplement.

Study Treatment Plan and Assessments
Treatment was given for 14 cycles of 28 days per cycle, as shown in the Data Supplement. Obinutuzumab was given at a dose of 1,000 mg intravenously on days 1-2 (split dose), 8, and 15 of cycle 1 and day 1 of cycles 2-8. Ibrutinib 420 mg orally daily was given continuously in cycles 2-14. The protocol allowed single-agent ibrutinib to be continued after cycle 14 at the discretion of the investigator. Venetoclax was started on day 1 of cycle 3 at 20 mg orally daily, with an intrapatient dose ramp-up every 7 days to 50 mg, 100 mg, 200 mg, and finally, the target dose of 400 mg. Venetoclax was continued through cycle 14. Risk for TLS was assessed according to US venetoclax prescribing information, with TLS prophylaxis and hospitalization for dose ramp-up according to individual patient risk (Data Supplement). Use of granulocyte colony-stimulating factor was permitted and recommended for grade 4 neutropenia lasting ≥ 1 week or complicated by fever. No prophylactic anti-infective agents were mandated.

Response was assessed according to the iwCLL 2008 guidelines. Response assessment occurred twice, at midtherapy after cycle 8 and at the end of treatment, which was 2 months after completion of cycle 14. MRD testing was done by standard 10-color flow cytometry with a detection limit of < 1 × 10⁻⁴. The absolute numbers of T and natural killer (NK) cells in the blood were also determined using the same flow cytometry panel. Adverse events (AEs) were assessed and graded using the Common Terminology Criteria for Adverse Events v4.03 from the National Cancer Institute, except for hematologic AEs. Hematologic AEs were assessed and graded according to the disease-specific iwCLL 2008 criteria (Data Supplement).

Measures of cognitive function and health-related quality of life were obtained serially during study treatment. The Patient-Reported Outcomes Measurement Information System Version 2.0 Cognitive Function-Concerns (PROMIS-CF-Concerns) 8-item short form was used to assess cognitive complaints. The National Institutes...
of Health Toolbox Auditory Verbal Learning Test (AVLT) was used to assess episodic memory. The Short Form-36 Health Survey (SF-36) is a 36-item questionnaire that was used to assess health-related quality of life. Details of psychological measures are included in the Data Supplement.

### Statistical Design and Analysis

The primary end point was the rate of CR with undetectable MRD in both the blood and bone marrow at the end of treatment assessment 2 months following cycle 14. This was an intent-to-treat analysis where any patient who took ≥ 1 dose of study treatment was evaluable. The study was designed to detect an improvement in the MRD-undetectable CR rate from 10% (null hypothesis) to 30% (alternative hypothesis) with at least 90% power using an exact 1-stage phase II design and constraining the 1-sided α to 10%. The design required 25 evaluable patients per cohort, with at least 5 patients achieving the response to reject the null hypothesis. Additional methods are detailed in the Data Supplement.

### RESULTS

#### Patients and Follow-Up

A total of 50 patients were enrolled between August 3, 2015, and April 5, 2017, in 2 separate cohorts for TN (n = 25) and RR (n = 25) patients (Data Supplement). Baseline characteristics of patients are presented in Table 1.
patient demographics, disease characteristics, and laboratory values are listed by cohort in Table 1. The majority of patients (86%) completed the regimen and underwent response assessment. Seven patients (14%) discontinued treatment. Three patients discontinued treatment as a result of patient or investigator preference (TN, cycle 7; TN, cycle 10; and RR, cycle 14), and 3 patients discontinued as a result of AEs (neutropenia and colitis [TN, cycle 10], bleeding and diarrhea [TN, cycle 13], and neutropenia [RR, cycle 7]). One RR cohort patient discontinued treatment during cycle 1 as a result of the incidental finding of concomitant chronic myeloid leukemia.

The median total follow-up time for PFS was 24.2 months (range, 7.4-27 months) for TN patients and 21.5 months (range, 0.2-27.8 months) for RR patients.

**Efficacy**

The midtherapy ORR was 96% (95% CI, 80% to 100%; 24 of 25 patients) in TN patients and 92% (95% CI, 74% to 99%; 23 of 25 patients) in RR patients. At the end of therapy, the ORR was 84% (95% CI, 64% to 95%; 21 of 25 patients) in TN patients and 88% (95% CI, 69% to 97%; 22 of 25 patients) in RR patients. Responses are shown in Figure 1. The most frequent response at both assessments was partial remission (PR), and all PRs were a result of small residual lymph node diameters > 1.5 cm. At the end-of-treatment assessment, the median greatest lymph node diameters were 2 cm (range, 1.6-3.5 cm) and 2 cm (range, 1.6-3.4 cm) in TN patients (n = 13) and RR patients (n = 11), respectively.

The primary study end point was MRD-undetectable CR, which was achieved in 28% (95% CI, 12% to 49%) of TN patients and 28% (95% CI, 12% to 49%) of RR patients (7 of 25 patients in each cohort). No detectable MRD in both blood and marrow was seen in a significant fraction of patients with a PR at the end of treatment assessment (7 [54%] of 13 TN patients and 4 [36%] of 11 RR patients; Data Supplement).

MRD was assessed in the blood and marrow at each response assessment using high-sensitivity flow cytometry. Undetectable MRD was defined as no detectable CLL in both the blood and the bone marrow. At the end of treatment, 67% of TN patients (14 of 21 patients) and 50% of RR patients (11 of 22 patients) had undetectable MRD (Data Supplement).

To determine how quickly leukemia was eliminated from the blood, the percentage of patients with MRD in the blood was plotted (Fig 2). Because of the limit of detection of the flow cytometry assay and small number of positive (v absent) cells on prespecified analysis gates specific to CLL, patients occasionally changed between having undetectable and detectable MRD.24

We performed a univariable analysis to determine whether any baseline patient or disease characteristics were associated with achieving an MRD-undetectable CR. Variables included prior treatment, baseline TLS risk category, IGHV status, Zap-70 methylation status, complex karyotype, fluorescence in situ hybridization panel markers, and baseline laboratory values. None were associated with a response of MRD-undetectable CR (P > .05 for all
variables; Data Supplement). We repeated the analysis to evaluate the association of these same characteristics with achieving MRD-undetectable status. This analysis also did not identify any associations ($P > .05$ for all variables; Data Supplement).

The median PFS and overall survival times were not reached in either cohort (Fig 3). There was 1 death in the study as a result of sepsis in a TN patient approximately 8.7 months after treatment was discontinued because of neutropenic colitis. One RR patient developed disease progression 11.2 months after finishing treatment. He started ibrutinib and achieved a response that is ongoing.

**Safety**

The treatment regimen was tolerable, and 6% of patients (3 of 50 patients) discontinued treatment as a result of AEs.
<table>
<thead>
<tr>
<th>Adverse Event*</th>
<th>TN Patients (n = 25)</th>
<th>RR Patients (n = 25)</th>
<th>All Patients (N = 50)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Grade 1-2</td>
<td>Grade 3-4</td>
<td>Any Grade</td>
</tr>
<tr>
<td>Neutrophil count decreased</td>
<td>9 (36)</td>
<td>14 (56)</td>
<td>23 (92)</td>
</tr>
<tr>
<td>Platelet count decreased</td>
<td>13 (52)</td>
<td>10 (40)</td>
<td>23 (92)</td>
</tr>
<tr>
<td>Hypertension</td>
<td>10 (40)</td>
<td>12 (48)</td>
<td>22 (88)</td>
</tr>
<tr>
<td>Hypocalcemia</td>
<td>20 (80)</td>
<td>20 (80)</td>
<td>21 (84)</td>
</tr>
<tr>
<td>Fatigue</td>
<td>20 (80)</td>
<td>2 (8)</td>
<td>22 (88)</td>
</tr>
<tr>
<td>Bruising</td>
<td>19 (76)</td>
<td>19 (76)</td>
<td>18 (72)</td>
</tr>
<tr>
<td>Infusion-related reaction</td>
<td>20 (80)</td>
<td>20 (80)</td>
<td>17 (68)</td>
</tr>
<tr>
<td>Myalgia</td>
<td>17 (68)</td>
<td>17 (68)</td>
<td>19 (76)</td>
</tr>
<tr>
<td>Hyperglycemia</td>
<td>17 (68)</td>
<td>1 (4)</td>
<td>18 (72)</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>15 (60)</td>
<td>1 (4)</td>
<td>16 (64)</td>
</tr>
<tr>
<td>Hyperuricemia</td>
<td>13 (52)</td>
<td>1 (4)</td>
<td>14 (56)</td>
</tr>
<tr>
<td>Mucositis oral</td>
<td>19 (76)</td>
<td>19 (76)</td>
<td>13 (52)</td>
</tr>
<tr>
<td>Nausea</td>
<td>18 (72)</td>
<td>18 (72)</td>
<td>13 (52)</td>
</tr>
<tr>
<td>Weight gain</td>
<td>17 (68)</td>
<td>17 (68)</td>
<td>14 (56)</td>
</tr>
<tr>
<td>Dyspepsia</td>
<td>17 (68)</td>
<td>17 (68)</td>
<td>12 (48)</td>
</tr>
<tr>
<td>Arthralgia</td>
<td>14 (56)</td>
<td>1 (4)</td>
<td>15 (60)</td>
</tr>
<tr>
<td>Headache</td>
<td>14 (56)</td>
<td>14 (56)</td>
<td>11 (44)</td>
</tr>
<tr>
<td>AST increased</td>
<td>10 (40)</td>
<td>2 (8)</td>
<td>12 (48)</td>
</tr>
<tr>
<td>Rash, maculopapular</td>
<td>17 (68)</td>
<td>17 (68)</td>
<td>8 (32)</td>
</tr>
<tr>
<td>Constipation</td>
<td>15 (60)</td>
<td>15 (60)</td>
<td>9 (36)</td>
</tr>
<tr>
<td>Chills</td>
<td>13 (52)</td>
<td>13 (52)</td>
<td>10 (40)</td>
</tr>
<tr>
<td>Cough</td>
<td>12 (48)</td>
<td>12 (48)</td>
<td>11 (44)</td>
</tr>
<tr>
<td>Anemia</td>
<td>9 (36)</td>
<td>1 (4)</td>
<td>10 (40)</td>
</tr>
<tr>
<td>Hypokalemia</td>
<td>12 (48)</td>
<td>12 (48)</td>
<td>7 (28)</td>
</tr>
<tr>
<td>Upper respiratory infection</td>
<td>11 (44)</td>
<td>11 (44)</td>
<td>9 (36)</td>
</tr>
<tr>
<td>Hypoalbuminemia</td>
<td>13 (52)</td>
<td>13 (52)</td>
<td>8 (32)</td>
</tr>
<tr>
<td>Paresthesia</td>
<td>13 (52)</td>
<td>13 (52)</td>
<td>8 (32)</td>
</tr>
<tr>
<td>Sinusitis</td>
<td>7 (28)</td>
<td>7 (28)</td>
<td>13 (52)</td>
</tr>
<tr>
<td>Anorexia</td>
<td>13 (52)</td>
<td>13 (52)</td>
<td>7 (28)</td>
</tr>
<tr>
<td>Sinus bradycardia</td>
<td>9 (36)</td>
<td>9 (36)</td>
<td>11 (44)</td>
</tr>
<tr>
<td>Blood bilirubin increased</td>
<td>11 (44)</td>
<td>11 (44)</td>
<td>8 (32)</td>
</tr>
<tr>
<td>Dyspepsia</td>
<td>9 (36)</td>
<td>9 (36)</td>
<td>10 (40)</td>
</tr>
<tr>
<td>Epistaxis</td>
<td>11 (44)</td>
<td>11 (44)</td>
<td>8 (32)</td>
</tr>
<tr>
<td>Sore throat</td>
<td>12 (48)</td>
<td>12 (48)</td>
<td>7 (28)</td>
</tr>
<tr>
<td>Back pain</td>
<td>11 (44)</td>
<td>11 (44)</td>
<td>7 (28)</td>
</tr>
<tr>
<td>Allergic rhinitis</td>
<td>8 (32)</td>
<td>8 (32)</td>
<td>9 (36)</td>
</tr>
<tr>
<td>Creatinine increased</td>
<td>8 (32)</td>
<td>8 (32)</td>
<td>9 (36)</td>
</tr>
<tr>
<td>Insomnia</td>
<td>11 (44)</td>
<td>11 (44)</td>
<td>6 (24)</td>
</tr>
<tr>
<td>Localized edema</td>
<td>9 (36)</td>
<td>9 (36)</td>
<td>8 (32)</td>
</tr>
<tr>
<td>Dizziness</td>
<td>9 (36)</td>
<td>9 (36)</td>
<td>6 (24)</td>
</tr>
<tr>
<td>ALT increased</td>
<td>5 (20)</td>
<td>1 (4)</td>
<td>6 (24)</td>
</tr>
</tbody>
</table>

(continued on following page)
Table 2 lists the frequent or serious AEs. A complete summary of AEs is provided in the Data Supplement.

The most frequent type of AE was hematologic. Neutropenia was experienced by 94% of patients, and 90% of patients had thrombocytopenia. Neutropenia was the most frequent grade 3-4 AE, with 66% of patients having grade 3-4 neutropenia. Despite this, only 1 patient experienced febrile neutropenia. When hematologic AEs were plotted over the course of treatment, there appeared...
to be more cytopenias in earlier treatment cycles (Data Supplement).

The most frequent nonhematologic AEs of any grade attributed to treatment were hypertension (82%), hypocalcemia (82%), fatigue (78%), bruising (74%), infusion-related reactions (74%), myalgia (72%), hyperglycemia (66%), diarrhea (64%), hyperuricemia (64%), oral mucositis (64%), nausea (62%), weight gain (62%), dyspepsia (58%), arthralgia (56%), headache (52%), and increased AST (50%). Mucositis was limited to oral ulcers. The only nonhematologic grade 3-4 AEs experienced by
10% of patients were hypertension (38%) and hypotension (10%). Ten percent of patients experienced atrial fibrillation. No patients experienced clinical or laboratory TLS in either cohort.

Changes in NK- and T-Cell Levels

The mean NK cells in the blood decreased significantly by the end of treatment (average decrease, $-675,000/\mu L$; 95% CI, $-861,000/\mu L$ to $-488,000/\mu L$; $P < .0001$). By 8 months after treatment, there was some increase ($P = .002$), but NK cells remained an average of 628,000/\mu L (95% CI, $-809,000/\mu L$ to $-447,000/\mu L$; $P < .0001$) below the pretreatment number. On average and across time, the RR cohort had lower NK cell levels in the blood than the TN cohort (mean difference, $-176,000/\mu L$; 95% CI, $-325,000/\mu L$ to $-28,000/\mu L$; $P = .01$) with no strong evidence that NK cell changes differed by cohort ($P = .052$; Data Supplement).

Likewise, decreases in CD4 and CD8 T cells across time were observed. The baseline mean CD4+ T-cell absolute number was lower at end of treatment with an average decrease of 1,356,000/\mu L (95% CI, $-1,685,000/\mu L$ to $-1,026,000/\mu L$; $P < .0001$). At 8 months after treatment, the T-cell level remained decreased ($P < .0001$). The mean CD8+ T-cell absolute number decreased by 901,000/\mu L on average at the end of treatment (95% CI, $-1,236,000/\mu L$ to $-566,000/\mu L$; $P < .0001$) and 8 months after treatment (95% CI, $-1,237,000/\mu L$ to $-564,000/\mu L$; $P < .0001$).

The CD4+ T cells were 503,000/\mu L lower (95% CI, $-822,000/\mu L$ to $-183,000/\mu L$; $P = .002$) on average in the RR group, but there was no significant difference in CD8+ T cells between groups. The descriptive summary of NK- and T-cell data and results of generalized linear models are provided in the Data Supplement.

Psychological Outcomes

Overall, the regimen did not have an adverse impact on objective measures of episodic memory and verbal fluency or on self-reported cognitive complaints, and some improvements were found. No significant changes in cognitive complaints were detected over the course of the treatment period (Wald $\chi^2$, 10.14; $P > .05$), although pairwise comparisons reflected significant changes from baseline to specific time points during treatment. Self-reported cognitive complaints (PROMIS-CF-Concerns) decreased in frequency from baseline (estimated marginal mean [EMM], 50.49) to cycle 1 (EMM, 53.18; $P = .008$) and to cycle 2 (EMM, 53.79; $P = .04$). Relative to baseline, cognitive complaints remained at similar levels during the venetoclax ramp-up in cycle 3 (EMM, 52.57; $P = .09$) but declined in cycle 6 (EMM, 52.42; $P = .02$), before returning to baseline levels by cycle 12 (EMM, 52.03; $P > .05$; Fig 4A).

DISCUSSION

The regimen of obinutuzumab, ibrutinib, and venetoclax met its primary goal of achieving deep remissions with a fixed-duration combination of targeted agents. The ORR compares favorably to that achieved with fludarabine, cyclophosphamide, and rituximab or obinutuzumab and venetoclax, which are also fixed-duration regimens.5,12 The regimen of obinutuzumab, ibrutinib, and venetoclax in this study produced deep remissions (CR and PR), with 67% of TN patients and 50% of RR patients having undetectable MRD in the blood and the marrow after treatment. Achieving MRD-undetectable status predicts a longer PFS after chemoimmunotherapy and with venetoclax regimens.5,25-28 Although longer follow-up is required to determine the significance of achieving undetectable MRD with this regimen, MRD status may be a better predictor of PFS than CR and thus represent a more suitable primary end point for future studies. However, using MRD as a surrogate end point requires close attention to potential complications and long-term toxicities that can occur with more aggressive therapies.

It is difficult to compare this regimen to ibrutinib and venetoclax combination studies because of differences in design and small sample size.29-31 For example, a phase II study of ibrutinib and venetoclax had a primary end point of best response at any time rather than an intent-to-treat analysis, although rates of undetectable MRD in the bone...
marrow were similar at a comparable time point. This regimen has shorter drug exposure but higher rates of neutropenia with the addition of obinutuzumab. Although studies with rituximab show little benefit added to ibrutinib or venetoclax, recent evidence suggests that obinutuzumab may be beneficial, and larger studies with longer follow-up are needed to determine the utility of this approach. We did not identify any characteristics associated with achieving MRD-undetectable status or a CR with undetectable MRD, which is not surprising because responses to both ibrutinib and venetoclax are similar in high-risk patients compared with intermediate- and low-risk patients. The analysis was limited by the low statistical power to detect such associations; for example, only 4 patients (and only 1 patient in the RR group) had del(17p)(p13.1). However, del(17p)(p13.1) may be associated with a shorter PFS after longer follow-up.

The study of any new regimen includes an assessment of its toxicities. There were high rates of grade 3-4 neutropenia (66%) and thrombocytopenia (36%). Although this did not result in many severe medical consequences, these rates are higher than similar doublets. This study enrolled a younger population, and the tolerability in older patients is unknown.

The long-term outcome of immune function is also important. Although the immune effects of ibrutinib have been well described, including recovery of exhausted T-cell function, few reports exist with venetoclax. We showed that circulating numbers of NK and T cells were lower after treatment. It is uncertain whether this effect will be sustained or will heighten risks for major infections or second malignancies.

For any therapeutic intervention, it is important to understand its effect on patients beyond capturing physical AEs. Up to 70% of patients with cancer receiving traditional chemotherapies exhibit measurable cognitive impairment. In CLL specifically, chemotherapy has been found to negatively affect health-related quality of life, although recent studies show that newer treatments can restore health-related quality of life and negative effects may not be seen.

In contrast to chemotherapy, this regimen was not associated with diminished cognitive performance. Rather, patients exhibited maintenance, or even improvement, of cognitive performance. This is valuable for all patients but has particular implications for those who require intellectual capacity for their employment or for older adults who may be more susceptible to treatment-related cognitive dysfunction. Scores on a measure of self-reported cognitive complaints (PROMIS-CF-Concerns) did not reflect an increase in cognitive complaints. Because this measure is known to reflect affective symptoms, these data are consistent with maintenance of normative levels of mental health–related quality of life. Our study adds new information by demonstrating our regimen led to improvements in cognitive performance and physical health–related quality of life.

The combination of obinutuzumab, ibrutinib, and venetoclax for a fixed course was tolerable and resulted in high rates of response and undetectable MRD. This regimen should not be used outside of a clinical trial and is currently being compared with ibrutinib and obinutuzumab in 2 phase III cooperative group trials (ClinicalTrials.gov identifiers: NCT03701282 and NCT03737981).

CLINICAL TRIAL INFORMATION
NCT02427451

AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST AND DATA AVAILABILITY STATEMENT
Disclosures provided by the authors and data availability statement (if applicable) are available with this article at DOI https://doi.org/10.1200/JCO.20.00491.

AUTHOR CONTRIBUTIONS
Conception and design: Kerry A. Rogers, Ying Huang, Amy S. Ruppert, Barbara L. Andersen, Jeffrey A. Jones, John C. Byrd
Administrative support: Christin Banks
Provision of study materials or patients: Kerry A. Rogers, Barbara L. Andersen, Farrukh T. Awan, Seema A. Bhat, Allison Dean, Margaret Lucas, Cara Grantier, Kami J. Maddocks, Jeffery A. Jones, Jennifer A. Woyach, John C. Byrd

Support by Genentech and, in part, by the Four Winds Foundation, Leukemia and Lymphoma Society, Vysis (part of Abbott Molecular), National Cancer Institute Grants No. R01 CA177292 and R35 CA197734 (J.C.B.), and The Ohio State University Comprehensive Cancer Center and the National Institutes of Health under Grant No. P30 CA016058. K.A.R. is a Scholar in Clinical Research of the Leukemia and Lymphoma Society. D.M.W. is supported by a Pelotonia fellowship.

Affiliations
1Division of Hematology, The Ohio State University, Columbus, OH
2The Ohio State University Comprehensive Cancer Center, Columbus, OH
3Department of Pathology, The Ohio State University, Columbus, OH
4Department of Psychology, The Ohio State University, Columbus, OH

Corresponding Author
Kerry A. Rogers, MD, The Ohio State University, 410 W 12th Ave, Wyman Hall, CCC Rm 458, Columbus, OH 43210; e-mail: kerry.rogers@osumc.edu.

Prior Presentation

Combination Obinutuzumab, Ibrutinib, and Venetoclax in CLL

Affiliations

1Division of Hematology, The Ohio State University, Columbus, OH
2The Ohio State University Comprehensive Cancer Center, Columbus, OH
3Department of Pathology, The Ohio State University, Columbus, OH
4Department of Psychology, The Ohio State University, Columbus, OH

Corresponding Author
Kerry A. Rogers, MD, The Ohio State University, 410 W 12th Ave, Wyman Hall, CCC Rm 458, Columbus, OH 43210; e-mail: kerry.rogers@osumc.edu.

Prior Presentation

Support
Supported by Genentech and, in part, by the Four Winds Foundation, Leukemia and Lymphoma Society, Vysis (part of Abbott Molecular), National Cancer Institute Grants No. R01 CA177292 and R35 CA197734 (J.C.B.), and The Ohio State University Comprehensive Cancer Center and the National Institutes of Health under Grant No. P30 CA016058. K.A.R. is a Scholar in Clinical Research of the Leukemia and Lymphoma Society. D.M.W. is supported by a Pelotonia fellowship.
REFERENCES


ACKNOWLEDGMENT

We acknowledge the members of the study team at The Ohio State University for their dedication to this study. We thank the clinical teams who provided care for the study patients as well as the participating patients and those who support them.
AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Phase II Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naïve and Relapsed or Refractory Chronic Lymphocytic Leukemia

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO’s conflict of interest policy, please refer to www.asco.org/wc or ascopubs.org/jco/authors/author-center.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).

Kerry A. Rogers
Consulting or Advisory Role: Acerta Pharma, AstraZeneca, Pharmacyclics, Abbvie
Research Funding: Genentech (Inst), Abbvie (Inst), Janssen (Inst)
Travel, Accommodations, Expenses: AstraZeneca

Lynne V. Abruzzo
Patents, Royalties, Other Intellectual Property: Royalties from a licensing agreement for a patent held by the University of Maryland

Farrukh T. Awan
Consulting or Advisory Role: Novartis, Gilead Sciences, AstraZeneca, Janssen Oncology, Abbvie, Genentech, Celgene, Pharmacyclics, Sunesis Pharmaceuticals, Blueprint Medicines, DAVA Pharmaceuticals, Medscape, Clinical Care Options, MEI Pharma, Verastem, Karyopharm Therapeutics
Speakers’ Bureau: AstraZeneca, Abbvie
Research Funding: Innate Pharma, Pharmacyclics

Seema A. Bhat
Consulting or Advisory Role: Janssen

Cara Grantier
Consulting or Advisory Role: Pharmacyclics/Janssen

Gerard Lozanski
Research Funding: Genentech (Inst)

Kami J. Maddocks
Honoraria: Pharmacyclics, Bayer, Novartis, Teva, Celgene, Seattle Genetics, MorphoSys
Research Funding: Pharmacyclics, Merck, Bristol-Myers Squibb

Jeffrey A. Jones
Employment: Celgene, Bristol-Myers Squibb
Stock and Other Ownership Interests: Celgene, Bristol-Myers Squibb

Jennifer A. Woyach
Consulting or Advisory Role: Pharmacyclics, Janssen, AstraZeneca, ArQule
Research Funding: Janssen, Karyopharm Therapeutics, MorphoSys, Verastem, Loxo, Abbvie

John C. Byrd
Honoraria: Pharmacyclics, AstraZeneca, Novartis, Syndex, Trillium Therapeutics
Consulting or Advisory Role: Acerta Pharma, Pharmacyclics, Genentech, Jazz Pharmaceuticals
Research Funding: Acerta Pharma (Inst), Pharmacyclics (Inst)

No other potential conflicts of interest were reported.